Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment

Exclusion Criteria

• •Allergy or intolerance to N-Acetylcysteine
• •Women who are pregnant or lactating
• •Current use of NAC or any supplement containing N-Acetylcysteine (must agree not to take any such supplement throughout study participation)
• •Use of carbamazepine or nitroglycerin within 14 days of randomization
• •Current enrollment in treatment for cannabis dependence
• •Any use of synthetic cannabinoids (such as K2/Spice) in the 30 days prior to screening or during the period between screening and randomization
• •Current substance dependence, other than cannabis or nicotine
• •Urine drug screen positive for any drug of abuse other than cannabis or amphetamines at the randomization visit (Only participants who have a valid prescription for amphetamines (e.g., for ADHD) may be included)
• •Urine drug screen positive for amphetamines at the randomization visit without having a valid prescription for it
• •Maintenance treatment with buprenorphine or methadone
• •Recent history of asthma (within the last 3 years)
• •History of seizure disorder, bipolar disorder, schizophrenia, or other significant or unstable medical or psychiatric illness that may place the participant at increased risk in the judgment of the medical clinician
• •Significant risk of homicide or suicide